Nipah scare: 674 people on contact list across Kerala; 12 kept in isolation in Malappuram
Among them, 131 are from Malappuram, 426 from Palakkad, 115 from Kozhikode, and one each from Ernakulam and Thrissur, the minister stated.
Twelve individuals are kept in isolation and receiving treatment, while 88 samples have tested negative so far in Malappuram.
As many as 81 people from Malappuram, 2 from Palakkad, and 1 from Ernakulam have been removed from the contact list based on the completion of their isolation period.
Seventeen people are currently in isolation in Palakkad. Statewide, 32 people fall under the highest-risk category and 111 are being monitored under the high-risk category, she mentioned.
George has directed the One Health Centre for Nipah Research to document all matters related to the outbreak. Earlier, an ICMR team visited Malappuram to assess the situation.
The update arrived as Kerala reported a second Nipah case in the Palakkad district after the demise of a 58-year-old man from Kumaramputhur near Mannarkkad. He tested positive for the virus and died at a private hospital in Perinthalmanna.
Meanwhile, a contact list has been prepared in the case, said George, adding the government is awaiting confirmation from the Pune Institute of Virology.
The minister added that the patient died on July 12, and his samples tested positive in a test conducted at Manjeri Medical College.
The Kerala government has issued an alert to hospitals in Palakkad, Malappuram, Kozhikode, Kannur, Wayanad, and Thrissur districts of the state.
Apart from this, the government directed field-level activities to intensify and continue fever surveillance. Further monitoring will be carried out, including the mobile tower location. The minister also directed the team to be strengthened in case another case is found.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
28 minutes ago
- Business Standard
Govt scheme helps Indians save money on medicines: You can benefit, too
Medicine costs can weigh heavily on household budgets, especially for those managing chronic conditions. But the government says that its scheme is helping Indians manage such costs. Jan Aushadhi Kendras (JAKs) have helped citizens to save around Rs 38,000 crore in 11 years, according to data presented to Parliament by the Ministry of Chemicals and Fertilisers. There were 16,912 Jan Aushadhi stores nationwide as of June, providing affordable generic medicines and surgical products, according to a PTI report. What is the Jan Aushadhi scheme? Launched in 2008 and revamped in 2015, the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) aims to make quality medicines available at affordable prices. Generic drugs, sold under their chemical name rather than a brand, are said to be just as effective as their branded counterparts. According to PMBJP's website, the scheme covers: -2,110 medicines and 315 surgical products -61 surgical equipment categories -Medicines priced 50-80 per cent lower than popular branded options Health care costs PTI reported, Anupriya Patel, Minister of State for Health and Family Welfare, told Rajya Sabha the scheme has helped people to reduce their out-of-pocket expenses on health. According to data from National Health Accounts, such expenses fell from 62.6 per cent of total health expenditure in 2014-15 to 39.4 per cent in 2021-22. The government now plans to expand the network to 25,000 kendras by March 2027. Branded vs Jan Aushadhi: A quick comparison A look at the price list of common medicines shows the steep difference between Jan Aushadhi and branded products: Medicine Name Jan Aushadhi Price (₹) Popular Brand Price (₹) Telmisartan 40mg (BP) 2.26 (per tab) 10–12 Metformin 500mg 1.06 (per tab) 4–6 Atorvastatin 10mg 3.19 (per tab) 7–10 Pantoprazole 40mg 2.20 (per tab) 6–8 Amoxicillin 500mg 1.80 (per cap) 5–7 Paracetamol 500mg 0.7 (per tab) 1-3 Source: Jan Aushadhi price list, 30 July 2025; market rates from pharmacy portals Should you switch? If you're managing long-term health conditions like diabetes, hypertension, or acidity, switching to Jan Aushadhi equivalents could lead to monthly savings. However, always consult your doctor before switching brands, as not all formulations may be identical in inactive ingredients or in dosage form.
The Hindu
an hour ago
- The Hindu
How far have we come in providing personalised radiation treatment for cancer patients?
Radiotherapy, also known as radiation oncology or radiation therapy, is an important arm of cancer therapy. It involves the use of high-energy ionizing radiation to predominantly treat malignancies, as well as certain benign conditions. In India, due to lack of awareness and inadequate cancer screening initiatives, a majority of cancer patients seek medical help when the disease is locally advanced, and hence are candidates requiring multi-modality treatment including various combinations of surgery, radiotherapy, chemotherapy, biological therapy and immunotherapy. Nearly 70% of cancer patients need radiotherapy as a part of their cancer treatment protocol, where its role may be a primary curative treatment, additional or adjunct treatment or palliative therapy to relieve symptoms in advanced disease stages. Also Read: ICMR study finds only 28.5% of cancer patients receive radiotherapy in India Understanding radiotherapy There are 2 primary treatment modalities in radiotherapy: teletherapy or external beam radiotherapy and brachytherapy. In the former, the patient is placed at a distance from the radiation-generating equipment (generating high-energy x rays or gamma radiation) and by virtue of the beam divergence, a homogenous dose is delivered to the tumour tissue. In brachytherapy, radiation-emitting radioactive sources are directly placed in contact with the tumour tissue and subsequently removed after a specific period of time, thereby delivering a high dose to the tumour directly. The last two decades have seen significant strides in the field of radiation oncology. Technological developments in hardware and software industries have led to development of equipment enabling high precision radiation delivery with sub-millimetre accuracy, resulting in better tumour control and reduction in treatment-related side effects arising out of damage to normal tissues adjacent to the tumour. Until a few years ago, access to this high precision radiotherapy treatment was restricted to large metropolitan cities. With the active involvement of government health agencies (both at the Centre and State levels) along with public private partnerships, there is currently a focussed attempt to reduce this disparity and improve the availability of radiotherapy treatment at most district-level hospitals. Contemporary radiotherapy treatment Contemporary high precision radiotherapy treatment techniques such as Intensity modulated radiotherapy (IMRT), Image Guided Radiotherapy (IGRT), Volumated Arc therapy (VMAT/Rapid Arc), Stereotactic Radiosurgery and Stereotactic Radiotherapy (SRS and SRT), have enabled treatment of cancer tissues with higher radiation doses and with preferential sparing of normal tissue. These techniques have also enabled the feasibility of organ preservation in daily practice. In spite of these benefits, all cancer patients undergoing radiotherapy do not get cured of cancer. An important limitation of present-day cancer treatment, including radiation therapy, is that the response of a tumour to treatment varies from person to person ranging from complete response to partial response and in some cases, disease progression despite treatment. This is due to differences in the genetic and protein composition of the tumours which varies from patient to patient and which can influence treatment outcomes. Another important limitation is treatment-related side effects, which vary from patient to patient and can interfere with treatment compliance necessitating lifestyle modifications during, and post treatment. In simple terms 'one size does not fit all'. Although the prescribed radiotherapy treatment might be the global established standard of care for a particular disease condition and stage, individual variations in treatment response and tolerance are the norm, which cannot currently be predicted based on any assessment tool. While available radiotherapy guidelines are mainly based on the average response of disease population to treatment, this approach fails to account for individual tumour variations with respect to their molecular and genetic signature as well as patient heterogeneity with respect to their demography, genetic makeup and pattern of lifestyle. There is an unmet need to develop markers which can predict or identify non-responders to radiation and those patients who are likely to develop disease progression while on treatment. There is also an urgent need to identify patients who are likely to suffer significant toxicity and discontinue treatment. In this regard, there exists an unmet need to develop drugs which can reduce radiation- related toxicity without interfering with the radiation's anti-tumour capabilities. Can newer tech such as proton therapy solve the problem? The introduction of proton therapy in India along with its dosimetric capability of delivering radiation doses only at a particular range of depth within the patient's body, has significantly reduced early and late complications of radiotherapy with the latter being an important advantage in treatment of paediatric patients. But proton therapy is not a personalised radiotherapy solution and patients can still have residual disease or recurrent disease after proton therapy, based on the radiosensitivity of the tumour. Also, the limited availability of proton therapy presently in India and the high cost of treatment are other inherent issues that render it as a non-viable treatment solution for a majority of Indian patients who cannot afford the cost. Thus there is an inherent need for developing personalised radiotherapy treatment practises which can allow a physician to predict the possible treatment response and risk of recurrence of a particular disease based on its molecular and genetic composition. Such a personalised radiotherapy protocol would have the following advantages in that it can: Provide optimal radiation treatment tailored to each patient tumour's unique biological and clinical characteristics Predict tumour response to radiotherapy prior to initiation of treatment thereby avoiding treatment- related toxicity in potential non-responders Then the pertinent question which arises is whether such a personalised radiotherapy protocol or assessment tool is in existence or whether it can be developed? The answer is a resounding yes. The promise of research into genetics and AI In recent years, probing research in the field of molecular oncology, genetics and artificial intelligence (AI) are bringing the concept of personalized radiotherapy closer to actual realization. At one end, data-driven AI and deep learning models are being developed to identify predictors of radiation sensitivity. This information is being gathered by accessing huge quantities of data regarding tumour behaviour and their associated pathological and molecular characteristics collected over the years, and corelating them with the outcomes of radiotherapy treatment already delivered. The following areas of medical research are contributing in a big way to the development of personalised radiotherapy treatment in the near future. These include – Digital pathology – This involves acquisition and interpretation of pathology information in digital format and environment. This, in turn, improves rapid referral of cases between hospitals and doctors for expert opinions or second opinions and facilitates incorporation of digital training resources into pathology reporting, paving the way for integration of AI in pathological reporting. Radiomics in prognostication – This involves analysis of certain patterns and disease characteristics from radiological scans, and the use of this information to predict patient outcomes and treatment responses to cancer. Radiomics aims to provide more precise information to guide treatment decisions. Genomics and proteomics-based treatment decisions – The development of bioinformatics and its integration with tumour-related genetics and molecular information is being used to develop genomic and proteomic-based tumour biology panels, which can help in early diagnosis as well as predict response to treatment. This can lead to more personalised and effective cancer treatment strategies. AI-based adaptive radiotherapy – A revolutionary concept in radiotherapy, this involves the use of AI-based tools to analyse tumour-related changes during a course of radiotherapy. In adaptive RT, before a patient receives his scheduled daily radiotherapy treatment, he is subjected to a CT scan or MR images which are acquired on the radiotherapy machine, prior to treatment. These images acquired are interpreted by AI-based programmes, which then calculate changes in tumour geometry based on daily radiation response. The radiation plan is then altered real time, and adjusted on a daily basis to effectively target the tumour and reduce damage to healthy tissues. This approach enhances the therapeutic ratio of the treatment, potentially improving cure rates while minimising side effects. One other area of research which is going to influence personalised radiotherapy services positively, is work on nanoparticle technology, which can enable a higher concentration of drugs delivered directly inside the tumour or its related microenvironment thereby increasing radiotherapy associated tumour damage and minimising normal tissue damage. AI-driven assessment of oral and gastrointestinal microbiome changes in response to radiotherapy are also being assessed as a prognostic tool to predict radiation responses. Another important development is research aimed at integrating daily PET CT scans into adaptive radiotherapy (biological adaptive RT), which adds functional information of the treatment along with anatomical data to refine adaptive radiotherapy plans. Although a lot of research efforts are currently underway in multi-directional fields with a single-minded focus on enabling personalised cancer treatment strategies, a lot of validation needs to be further done in this regard to enable these modalities to be incorporated into daily treatment protocols. However, the good news is that we have indeed covered a lot of ground in realising this dream and the day is not far when the concept of personalised radiotherapy will be translated from the laboratory bench to bedside practise. (Dr. K. Satish Srinivas is professor and head of the department of radiation oncology, SRIHER, Chennai.
News18
2 hours ago
- News18
Two Arunachal districts secure top position in PMMVY enrollment
Itanagar, Jul 30 (PTI) Arunachal Pradesh has made significant strides in the implementation of the Pradhan Mantri Matru Vandana Yojana (PMMVY), with Anjaw and Pakke Kessang districts securing the top two positions nationally in percentage enrollment progress. According to the latest report of the Union Women and Child Development ministry, released on July 25, Anjaw district achieved a remarkable 354 per cent of its indicative enrollment target, ranking first in India. Pakke Kessang followed closely with 313 per cent, placing second nationwide. The progress has propelled Arunachal Pradesh's overall performance in the PMMVY rankings, lifting the state from the bottom tier to the 6th position among all states and union territories. Other districts of the state showing strong performance include Lower Dibang Valley (147%), Lower Siang (114%), and East Siang (61%), all of which have exceeded their set targets. However, districts such as Shi-Yomi, Lower Subansiri, and Leparada reported less than 10% progress, prompting officials to intensify outreach and registration efforts in those areas. The Pradhan Mantri Matru Vandana Yojana (PMMVY), a centrally sponsored flagship scheme by the Women and Child Development ministry is designed to support pregnant women and lactating mothers. The scheme is to provide maternity benefits to women belonging to socially and economically disadvantaged sections of society. The maternity benefit is to be provided to a woman for the first two living children, provided the second child is a girl. With renewed focus on grassroots implementation and awareness campaigns, state authorities remain optimistic about closing the gaps and ensuring full coverage across all 28 districts. PTI UPL UPL RG view comments First Published: July 30, 2025, 12:30 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
